Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest CD4 Stories

2009-04-10 08:32:49

The first antiretroviral treatments appeared in 1996. Since then, new and better drugs have been discovered that have almost turned AIDS into a chronic disease. Nevertheless, there is still room to improve the performance of the the therapeutic strategies used in clinical practice. This is shown by a study published in the online edition of The Lancet, suggesting that early administration of antiretroviral treatment reduces the rate of AIDS development and death in HIV-positive patients by...

2009-02-11 09:06:12

Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.These are the findings of two large international clinical trials presented today at the Conference on Retroviruses and...

2009-02-03 06:00:00

Therapeutic Approach Provides HIV-Resistant Immune Cells RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS. Based on Sangamo's zinc finger DNA-binding protein nuclease (ZFN) technology, SB-728-T has been shown in an animal model of HIV infection to lead to an increase in CD4+ T-cell...

2009-01-07 07:15:00

WALTHAM, Mass., Jan. 7 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, has introduced the pima(TM) analyzer, a unique test platform which allows immunological testing at Point-of-Care. The initial application of the instrument will be a first of its kind CD4 cell enumeration test. The instrument is one of several novel technologies under development at an Inverness...

2008-10-28 18:00:28

WASHINGTON and RICHMOND, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of data demonstrating that human CD4 T-cells can be made permanently resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)) resulting in an increase in CD4 T-cell counts and a reduction in viral load in an animal model of HIV infection. The presentation, entitled, "Establishment of HIV Resistant CD4 T-cells Using Engineered...

2008-10-27 06:00:07

By Steve Sternberg WASHINGTON -- A new analysis of the best time to begin HIV treatment found that starting early sharply improves survival, doctors said Sunday. Doctors say the new evidence is certain to prompt many doctors to change the way they treat patients, and to prompt health officials to begin examining the evidence underlying guidelines for treating the AIDS virus. The study of 8,374 patients in the USA and Canada showed that those treated later in the course of HIV infection...

2008-09-22 18:00:34

A simple test given to HIV/AIDS patients in southern Africa could extend their lives by nearly a year and save health-care costs at the same time, according to a new study by researchers at the Stanford University School of Medicine and the Palo Alto Veterans Affairs Health Care System. The technique, known as the CD4 test, would be particularly valuable if it were given to patients early in their disease, before they became ill with an AIDS-related infection, the researchers found. Use...

2008-08-05 09:01:31

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a phase 1 clinical trial that has begun enrolling patients. The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A....

2008-07-25 18:00:00

Reducing stress can bolster the immune system in human immunodeficiency virus, or HIV-positive adults, U.S. researchers said. CD4+ T lymphocytes, or CD4 T cells, are the brains of the immune system, coordinating its activity when the body comes under attack. They are also the cells that are attacked by HIV -- the virus slowly eats away at CD4 T cells, weakening the immune system. But the immune systems of HIV/AIDS patients face another enemy as well -- stress, which can accelerate CD4 T...

2008-06-30 09:03:37

RICHMOND, Calif., June 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the publication of data demonstrating that human immune system cells (CD4 T-cells) can be made resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)). The data suggest that the ZFN approach, which results in the permanent modification of the CCR5 gene encoding an important receptor for HIV infection, is a promising strategy for the treatment of HIV/AIDS....